Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FSHD region gene 2 family member L, pseudogene (FRG2LP) is classified as a pseudogene associated with the FRG2 gene family, which includes genes located proximal to the D4Z4 repeat array involved in facioscapulohumeral muscular dystrophy (FSHD)[1]. FRG2 itself has been investigated for its possible role in FSHD, but the FRG2LP gene is annotated as a pseudogene, which means it is not expected to code for a functional protein. There is currently no evidence of established biological activity, therapeutic relevance, or pharmacological targeting for FRG2LP in the literature or disease gene databases[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FSHD region gene 2 family member L, pseudogene (FRG2LP).